Benkui Zou
Overview
Explore the profile of Benkui Zou including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
140
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hou Z, Lai L, Wu H, Zou B, Xu N, Zhu D, et al.
J Cancer
. 2024 Jul;
15(14):4527-4533.
PMID: 39006086
Background: The Food and Drug Administration of the United States has approved several drugs for treating advanced metastatic renal cell carcinoma, including anti-vascular tyrosine kinase inhibitors (TKIs) and immune checkpoint...
2.
Xu M, Tan J, Zhu L, Ge C, Zhang Y, Gao F, et al.
Adv Sci (Weinh)
. 2023 Dec;
10(36):e2308024.
PMID: 38153358
No abstract available.
3.
Xu M, Tan J, Zhu L, Ge C, Zhang Y, Gao F, et al.
Adv Sci (Weinh)
. 2023 Aug;
10(28):e2302130.
PMID: 37544908
Underestimation of the complexity of pathogenesis in nonalcoholic steatohepatitis (NASH) significantly encumbers development of new drugs and targeted therapy strategies. Inactive rhomboid protein 2 (IRHOM2) has a multifunctional role in...
4.
Wang H, Li H, Yuan Y, Hao T, Zou B, Yu B, et al.
Transl Androl Urol
. 2022 May;
11(4):460-471.
PMID: 35558268
Background: Circulating tumor cells (CTCs) are considered useful prognostic factors for various cancers, and in 2014, our research group conducted a comparative experiment of CTC detection in patients with renal...
5.
Guo R, Liang Y, Zou B, Li D, Wu Z, Xie F, et al.
Front Oncol
. 2022 Mar;
12:842967.
PMID: 35252011
Background: Renal cell carcinoma (RCC) is one of the most common and lethal human urological malignancies around the world. Although many advancements in diagnostic and therapeutic strategies have been acquired,...
6.
Xu M, Tan J, Dong W, Zou B, Teng X, Zhu L, et al.
Nat Commun
. 2022 Feb;
13(1):1052.
PMID: 35217669
Systemic metabolic syndrome significantly increases the risk of morbidity and mortality in patients with non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). However, no effective therapeutic strategies are available,...
7.
Guo R, Zou B, Liang Y, Bian J, Xu J, Zhou Q, et al.
Cell Death Dis
. 2021 Jul;
12(7):689.
PMID: 34244473
Renal cell carcinoma is the second malignant tumors in the urinary system with high mortality and morbidity. Increasing evidence suggests that long non-coding RNAs (lncRNAs) play critical roles in tumor...
8.
Ning D, Cui K, Liu M, Ou Y, Wang Z, Zou B, et al.
Med Sci Monit
. 2021 Jan;
27:e926565.
PMID: 33408319
BACKGROUND The purpose of this study was to compare circulating tumor cells (CTCs)/circulating tumor microemboli (CTM) detection rates of the CellSearch and CTC-Biopsy systems in patients with gastric cancer (GC)....
9.
Bai M, Zou B, Wang Z, Li P, Wang H, Ou Y, et al.
Int Urol Nephrol
. 2018 Aug;
50(10):1801-1809.
PMID: 30120680
Background/aims: Detection of circulating tumor cells (CTCs) in cancer patients has diagnostic and prognostic importance. However, the clinical implications of CTC detection in patients with renal cell carcinoma (RCC) are...
10.
Zhou W, Zou B, Liu L, Cui K, Gao J, Yuan S, et al.
Oncotarget
. 2016 Sep;
7(45):74059-74073.
PMID: 27677076
MicroRNAs (miRs) are involved in the development and progression of hepatocellular carcinoma (HCC), but the regulatory mechanism of miR-98 in HCC still remains unclear. Here we found that miR-98 was...